Cytokinetics, Incorporated (CYTK)
After hours:
| Previous Close | 66.29 |
| Open | 66.72 |
| Bid | 65.44 x 200 |
| Ask | 65.61 x 200 |
| Day's Range | 65.53 - 68.76 |
| 52 Week Range | 25.98 - 110.25 |
| Volume | |
| Avg. Volume | 2,067,303 |
| Market Cap | 6.857B |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.45 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 95.06 |
GlobeNewswireCytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Clinical Trial presentations relating to SEQUOIA-HCM, (Safety, Efficacy, and Quantitative Understanding of Obstructi
GuruFocus.comEVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
Cytokinetics Inc (NASDAQ:CYTK), a biopharmaceutical company focused on the discovery and development of next-generation therapeutics for muscle diseases, has reported an insider sale according to a recent SEC filing.
- GlobeNewswire
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
Treatment with Aficamten for 48 Weeks is Associated with Improvements in Clinical Efficacy Endpoints, NYHA Class and Cardiac Biomarkers, Structure and FunctionSOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical study of aficamten in patients with hypertrophic cardi
